Results 221 to 230 of about 897,221 (299)

FXYD3 Promotes Tumor Progression by Binding With IRF7 to Regulate JAK2/STAT5 Signaling in Intrahepatic Cholangiocarcinoma

open access: yesAdvanced Science, EarlyView.
FXYD3 binds IRF7 via its 60–87aa domain, triggering a cGAS/STING‐mediated positive feedback loop amplified by type I interferon. This sustains JAK2/STAT5 activation, accelerating ICC progression. Targeting FXYD3 with siFXYD3@PEP suppresses tumors and enhances chemotherapy sensitivity. Abstract Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis,
Yan Zhou   +13 more
wiley   +1 more source

Rare presentation of incarcerated ventral hernia containing transverse colon diverticulitis. [PDF]

open access: yesJ Surg Case Rep
Abu Sba AMA   +5 more
europepmc   +1 more source

Colonic tuberculosis

open access: yesGastroenterology, 1979
A, Bretholz, M, Knoblauch
openaire   +2 more sources

ACSL5 Regulates Glucose Metabolism and Chemotherapy Sensitivity in Colorectal Cancer Cells under Glutamine Deficiency

open access: yesAdvanced Science, EarlyView.
Glutamine deprivation triggers ACSL5 upregulation in tumor cells, sustaining their viability via dual metabolic rewiring programs. ACSL5 enhances glycolysis by relieving p53's inhibition of PGAM1 while also sustaining mitochondrial respiration and TCA cycle flux through promoting IDH2 dimerization.
Shuai Tian   +11 more
wiley   +1 more source

LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1

open access: yesAdvanced Science, EarlyView.
LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li   +12 more
wiley   +1 more source

KRAS Withdrawal in Cholangiocarcinoma Leads to Immune Infiltration and Tumor Regression

open access: yesAdvanced Science, EarlyView.
Cholangiocarcinoma (CCA) driven by oncogenic KRAS depends on its continuous activation for tumor maintenance. Using a conditional KRAS model, the authors show that turning off KRAS triggers rapid tumor regression accompanied by immune cell infiltration and cytokine release. The findings uncover a KRAS–senescence–immune signaling axis and highlight KRAS
Youwei Qiao   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy